IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NEC
Go back to IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NEC| (NASDAQ: IDYA) | Delayed: 35.23 +1.00 (2.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.23 | 52 Week High | $ | |||
| Open | $34.00 | 52 Week Low | $ | |||
| Day High | $35.50 | P/E | N/A | |||
| Day Low | $33.81 | EPS | $ | |||
| Volume | 660,293 | |||||
